What is AN2 Therapeutics, Inc. (ANTX)?

AN2 Therapeutics, Inc. (ANTX) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ANTX?

The current price of ANTX is $3.86. Prices are updated in real time on Stocks360.

What is ANTX's price-to-earnings (PE) ratio?

ANTX's trailing twelve-month PE ratio is -3.61, based on current price and earnings per share data available on Stocks360.

What is ANTX's market capitalization?

ANTX's market capitalization is $145,661,875.00, placing it in the small-cap tier.

AN2 Therapeutics, Inc. (ANTX)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$3.86

Market Cap

$145.66M

PE (TTM)

-3.61

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-0.98

Day Range

$3.54 – $3.89

52-wk Range

$1.00 – $7.19

Avg Volume

N/A

Volume

239.62K

AN2 Therapeutics, Inc. (ANTX) is a publicly traded company in the Healthcare sector. Latest price: $3.86. Market cap $145.66M. Trailing PE -3.61. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 6 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-28 · $1.29 2026-10-27 · $3.86 (+199.22%)

Earnings

Most Recent

Aug 11, 2026

EPS $-0.18 vs est. $-0.24

Beat by $0.06

Next Earnings

Nov 5, 2026

EPS estimate $-0.20

Proprietary Signals

Signal snapshot temporarily unavailable.

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-3.61×
P/S (TTM)	0.00×
P/B	2.28×
P/FCF (TTM)	-4.75×
EV / EBITDA	-2.70×
EV / Sales	0.00×
Earnings Yield	-21.00%
Free Cash Flow Yield	-21.06%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$101.34M
Net Income (TTM)	-$30.58M
Free Cash Flow (TTM)	-$30.68M
Net Debt	-$44.32M
Working Capital	$74.41M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-53.52%
Return on Invested Capital	-51.01%